Page last updated: 2024-10-20

uric acid and Cough

uric acid has been researched along with Cough in 4 studies

Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.

Cough: A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.

Research Excerpts

ExcerptRelevanceReference
"To assess the efficacy and safety of febuxostat extended release (XR) and immediate release (IR) in patients with gout and normal or impaired renal function."9.30Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. ( Becker, MA; Castillo, M; Gunawardhana, L; Hunt, B; Kisfalvi, K; Saag, KG; Whelton, A, 2019)
"To assess the efficacy and safety of febuxostat extended release (XR) and immediate release (IR) in patients with gout and normal or impaired renal function."5.30Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. ( Becker, MA; Castillo, M; Gunawardhana, L; Hunt, B; Kisfalvi, K; Saag, KG; Whelton, A, 2019)
"Enalapril has similar effects to losartan on systemic blood pressure, renal function and serum UA in patients with CKD, but carries a higher risk of dry cough."4.89Enalapril versus losartan for adults with chronic kidney disease: a systematic review and meta-analysis. ( Feng, L; He, YM; Huo, DM; Liao, YH; Yang, ZH, 2013)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19901 (25.00)18.7374
1990's1 (25.00)18.2507
2000's0 (0.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Saag, KG1
Becker, MA1
Whelton, A1
Hunt, B1
Castillo, M1
Kisfalvi, K1
Gunawardhana, L1
He, YM1
Feng, L1
Huo, DM1
Yang, ZH1
Liao, YH1
Friedman, GD1
Siegelaub, AB1
Shionoiri, H1
Sugimoto, K1
Kosaka, T1
Kita, E1
Oda, H1
Ushikubo, T1
Goto, T1
Takasaki, I1
Yasuda, G1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout[NCT02139046]Phase 31,790 participants (Actual)Interventional2014-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Percentage of Participants With at Least One Gout Flare Requiring Treatment

"A participant was considered to have a gout flare if the following criteria were met:~Participant-reported acute particular pain typical of a gout attack that was deemed by participant and/or investigator to require treatment and was treated with colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs) or steroids, Participant experienced at least 3 or more of: 1) Joint swelling, 2) Redness, 3) Tenderness, 4) Pain, Participant experienced at least one or more of: 1) Rapid onset of pain, 2) Decreased range of motion, 3) Joint warmth, 4) Other symptoms similar to a prior gout flare." (NCT02139046)
Timeframe: Baseline to Month 3

Interventionpercentage of participants (Number)
Placebo20.7
Febuxostat IR 40 mg21.0
Febuxostat XR 40 mg22.8
Febuxostat IR 80 mg27.2
Febuxostat XR 80 mg26.6

Percentage of Participants With Serum Urate <5.0 mg/dL at Month 3

(NCT02139046)
Timeframe: Month 3

Interventionpercentage of participants (Number)
Placebo0.3
Febuxostat IR 40 mg15.7
Febuxostat XR 40 mg25.9
Febuxostat IR 80 mg42.6
Febuxostat XR 80 mg50.1

Percentage of Participants With Serum Urate <6.0 mg/dL at Month 3

(NCT02139046)
Timeframe: Month 3

Interventionpercentage of participants (Number)
Placebo0.6
Febuxostat IR 40 mg40.3
Febuxostat XR 40 mg48.2
Febuxostat IR 80 mg57.7
Febuxostat XR 80 mg61.1

Reviews

1 review available for uric acid and Cough

ArticleYear
Enalapril versus losartan for adults with chronic kidney disease: a systematic review and meta-analysis.
    Nephrology (Carlton, Vic.), 2013, Volume: 18, Issue:9

    Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biom

2013

Trials

2 trials available for uric acid and Cough

ArticleYear
Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study.
    Arthritis & rheumatology (Hoboken, N.J.), 2019, Volume: 71, Issue:1

    Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Colchicine; Cough; Creatinine; Delay

2019
Long-term therapy with an ACE inhibitor, temocapril, reduces microalbuminuria in essential hypertension.
    Hypertension research : official journal of the Japanese Society of Hypertension, 1998, Volume: 21, Issue:2

    Topics: Albuminuria; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Cough;

1998

Other Studies

1 other study available for uric acid and Cough

ArticleYear
Changes after quitting cigarette smoking.
    Circulation, 1980, Volume: 61, Issue:4

    Topics: Adult; Aged; Angina Pectoris; Blood Glucose; Blood Pressure; Cholesterol; Chronic Disease; Coronary

1980